Differential Psoriatic Effect of Imiquimod on Balb/c and Swiss Mice

Fathima Salwa; Murali Badanthadka; Lidwin D’Souza

doi:10.1055/s-0041-1726681

Journal of Health and Allied Sciences NU, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Journal of Health and Allied Sciences NU 2021; 11(03): 170-177
DOI: 10.1055/s-0041-1726681

Original Article

Differential Psoriatic Effect of Imiquimod on Balb/c and Swiss Mice

Fathima Salwa

¹Department of Pharmacology, NGSM Institute of Pharmaceutical Sciences, Mangalore, Karnataka, India

,

Murali Badanthadka

²Department of Nitte University Centre for Animal Research and Experimentation, NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Nitte (deemed to be) University, Paneer, Deralakatte, Mangalore, Karnataka, India

,

Lidwin D’Souza

³Department of Pharmacovigilance, Norwich Clinical Services, Bangalore, Karnataka, India

› Institutsangaben

Abstract

Introduction The influence of animal strain on psoriasis model development by imiquimod (IMQ) has been studied in Balb/c and Swiss mice.

Materials and Methods Female mice of either strain were challenged with 5% IMQ (62.5 mg on back skin, 10 mg on right ear). They were observed for the severity of the disease using Psoriasis area severity index (PASI), splenomegaly, and histopathological alterations. To validate the model, well-established antipsoriatic drug clobetasol (0.05%, 120 mg on the back skin, 10 mg on the right ear) was used. Additionally, to study the strain-dependent response to IMQ associated with oxidative stress, various antioxidant factors like superoxide dismutase (SOD), catalase (CT), and glutathione (GSH) were measured. Antioxidant natural product curcumin (1%, 150 mg on back skin, 12.5 mg on right ear) was used to evaluate the alleviation of oxidative stress on distinct mice strain.

Results PASI score, body weight, and histopathology indicated the development of disease in both the strains, severity, and stability of which was dependent on the particular strain. Splenomegaly suggested the systemic effect, which was comparable in both the stains. IMQ and its involvement in redox status were confirmed by an alteration in the activity of SOD, CT, and levels of GSH.

Conclusion This study demonstrated that, in the IMQ-induced psoriasis model, the genetic background has some impact on the disease severity, stability, and redox imbalance.

Keywords

Balb/c mice - clobetasol - curcumin - imiquimod - psoriasis - Swiss mice

Volltext

Referenzen

References
1 Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. Clin Exp Rheumatol 2015; 33 (05) Suppl 93): S2-S6
2 Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005; 64 (Suppl. 02) ii30-ii36
3 Schön MP, Manzke V, Erpenbeck L. Animal models of psoriasis-highlights and drawbacks. J Allergy Clin Immunol 2021; 147 (02) 439-455
4 van der Fits L, Mourits S, Voerman JS. et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009; 182 (09) 5836-5845
5 Flutter B, Nestle FO. TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis. Eur J Immunol 2013; 43 (12) 3138-3146
6 Yoshiki R, Kabashima K, Honda T. et al. IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producingδT cells. J Invest Dermatol 2014; 134 (07) 1912-1921
7 Zhang J, Lin Y, Li C. et al. IL-35 decelerates the inflammatory process by regulating inflammatory cytokine secretion and M1/M2 macrophage ratio in psoriasis. J Immunol 2016; 197 (06) 2131-2144
8 Duan Y, Dong Y, Hu H. et al. IL-33 contributes to disease severity in psoriasis-like models of mouse. Cytokine 2019; 119: 159-167
9 Niu XL, Huang Y, Gao YL. et al. Interleukin-18 exacerbates skin inflammation and affects microabscesses and scale formation in a mouse model of imiquimod-induced psoriasis. Chin Med J (Engl) 2019; 132 (06) 690-698
10 Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol 2010; 160 (04) 810-820
11 Kadam DP, Suryakar AN, Ankush RD, Kadam CY, Deshpande KH. Role of oxidative stress in various stages of psoriasis. Indian J Clin Biochem 2010; 25 (04) 388-392
12 Sunkari S, Thatikonda S, Pooladanda V, Challa VS, Godugu C. Protective effects of ambroxol in psoriasis like skin inflammation: exploration of possible mechanisms. Int Immunopharmacol 2019; 71: 301-312
13 Lin X, Huang T. Oxidative stress in psoriasis and potential therapeutic use of antioxidants. Free Radic Res 2016; 50 (06) 585-595
14 Gabr SA, Al-Ghadir AH. Role of cellular oxidative stress and cytochrome c in the pathogenesis of psoriasis. Arch Dermatol Res 2012; 304 (06) 451-457
15 Yin LL, Zhang Y, Guo DM, An K, Yin MS, Cui X. Effects of zinc on interleukins and antioxidant enzyme values in psoriasis-induced mice. Biol Trace Elem Res 2013; 155 (03) 411-415
16 Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organ J 2012; 5 (01) 9-19
17 Kaur M, Sharma S, Kukreja S. et al. Study of oxidative stress in patients of psoriasis. Int J Res Dermatol. 2016; 2 (04) 95-98
18 Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82 (01) 70-77
19 Kakkar P, Das B, Viswanathan PN. A modified spectrophotometric assay of superoxide dismutase. Indian J Biochem Biophys 1984; 21 (02) 130-132
20 Aebi H. Catalase in vitro. Methods Enzymol 1984; 105: 121-126
21 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193 (01) 265-275
22 Baker BS, Brent L, Valdimarsson H. et al. Is epidermal cell proliferation in psoriatic skin grafts on nude mice driven by T-cell derived cytokines?. Br J Dermatol 1992; 126 (02) 105-110
23 Denayer T, Stöhr T, Roy MV. Animal models in translational medicine: validation and prediction. New Horiz Transl Med 2014; 2: 5-11
24 Niculet E, Radaschin DS, Nastase F. et al. Influence of phytochemicals in induced psoriasis (Review).. Exp Ther Med 2020; 20 (04) 3421-3424
25 Bocheńska K, Smolińska E, Moskot M, Jakóbkiewicz-Banecka J, Gabig-Cimińska M. Models in the research process of psoriasis. Int J Mol Sci 2017; 18 (12) 2514
26 Di Domizio J, Conrad C, Gilliet M. Xenotransplantation model of Psoriasis. Methods Mol Biol 2017; 1559: 83-90
27 Badanthadka M, D’Souza L. Imiquimod induced psoriasis mice model: a promising tool for psoriasis research?. Res J Pharm Tech. 2020; 13 (07) 3508-3515
28 Swindell WR, Michaels KA, Sutter AJ. et al. Imiquimod has strain-dependent effects in mice and does not uniquely model human psoriasis. Genome Med 2017; 9 (01) 24
29 Terhorst D, Chelbi R, Wohn C. et al. Dynamics and transcriptomics of skin dendritic cells and macrophages in an imiquimod-induced, biphasic mouse model of psoriasis. J Immunol 2015; 195 (10) 4953-4961
30 Parmar KM, Itankar PR, Joshi A, Prasad SK. Anti-psoriatic potential of Solanum xanthocarpum stem in imiquimod-induced psoriatic mice model. J Ethnopharmacol 2017; 198: 158-166
31 Pukale SS, Sharma S, Dalela M. et al. Multi-component clobetasol-loaded monolithic lipid-polymer hybrid nanoparticles ameliorate imiquimod-induced psoriasis-like skin inflammation in Swiss albino mice. Acta Biomater 2020; 115: 393-409
32 Sun S, Zhang X, Xu M. et al. Berberine downregulates CDC6 and inhibits proliferation via targeting JAK-STAT3 signaling in keratinocytes. Cell Death Dis 2019; 10 (04) 274
33 Alvarez P, Jensen LE. Imiquimod treatment causes systemic disease in mice resembling generalized pustular psoriasis in an IL-1 and IL-36 dependent manner. Mediators Inflamm 2016; 2016: 6756138
34 Chen HH, Chao YH, Chen DY. et al. Oral administration of acarbose ameliorates imiquimod-induced psoriasis-like dermatitis in a mouse model. Int Immunopharmacol 2016; 33: 70-82
35 Zhang S, Liu X, Mei L, Wang H, Fang F. Epigallocatechin-3-gallate (EGCG) inhibits imiquimod-induced psoriasis-like inflammation of BALB/c mice. BMC Complement Altern Med 2016; 16 (01) 334
36 Mebius RE, Kraal G. Structure and function of the spleen. Nat Rev Immunol 2005; 5 (08) 606-616
37 Zhou Q, Mrowietz U, Rostami-Yazdi M. Oxidative stress in the pathogenesis of psoriasis. Free Radic Biol Med 2009; 47 (07) 891-905
38 Hosseini A, Hosseinzadeh H. Antidotal or protective effects of Curcuma longa (turmeric) and its active ingredient, curcumin, against natural and chemical toxicities: a review. Biomed Pharmacother 2018; 99: 411-421
39 Al-Zahaby SA, Salem ML. Abdul-Aziz3 KK. et al Comparative experimental studies on the spleen of young and aged balb/c and cd-1 mice. Int J Adv Res Biol Sci. 2017; 4 (12) 226-241
40 Pellegrini A, Guiñazú N, Aoki MP. et al. Spleen B cells from BALB/c are more prone to activation than spleen B cells from C57BL/6 mice during a secondary immune response to cruzipain. Int Immunol 2007; 19 (12) 1395-1402
41 Xu F, Xu J, Xiong X, Deng Y. Salidroside inhibits MAPK, NF-κB, and STAT3 pathways in psoriasis-associated oxidative stress via SIRT1 activation. Redox Rep 2019; 24 (01) 70-74
42 Baek JO, Byamba D, Wu WH, Kim TG, Lee MG. Assessment of an imiquimod-induced psoriatic mouse model in relation to oxidative stress. Arch Dermatol Res 2012; 304 (09) 699-706